UroCCR Database: French Research Network for Kidney Cancer -UroCCR

ConditionKidney Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux

About this trial

Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.

More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.

By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patient with kidney cancer

Patient with no opposition to collection of its data for the study

Disqualifiers

None

Trial population

Patients with Kidney cancer

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

    Procedure/Surgery

Treatment groups

30,000 Participants
are divided into 1 treatment group
Group A: Patients1 intervention

Trial outcomes

Primary outcomes

1

Promotion of Prospective Research Projects

Development and conduct of prospective research projects across a broad range of thematic fields related to kidney cancer .

Time frame
From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).

Secondary outcomes

1

Establishment of a Multicentre Annotated Biological Sample Collection

Annotation of biological samples collection and associated clinical data to support translational and clinical research in kidney cancer.

Time frame
From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
2

Advancement of Knowledge in Kidney Cancer Descriptive Epidemiology

Characterization of the incidence, prevalence, distribution, and trends of kidney cancer within the population

Time frame
From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
3

Advancement of Knowledge in Pharmacoepidemiology and Treatment Monitoring in Kidney Cancer

Evaluatation of treatment safety, efficacy, real-world indications, utilization patterns, and associated healthcare costs

Time frame
From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).
4

Advancement of Knowledge in Quality of Life and Patient-Reported Outcomes in Kidney Cancer

Assessment of quality of life, patient-reported outcomes (PROs), and patient-reported experiences (PREs), including the personal, familial, professional, and social impact of kidney cancer. Data may be collected through digital tools such as UroConnect

Time frame
From patient enrollment (Day 0) until the end of follow-up (death or withdrawal from the study).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.